SCHEMBL5367740

SCHEMBL5367740

Cc1cc(C)c(C=C2C(=O)Nc3ccc(C(=N)N)cc32)[nH]1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLK2 Q86UE8 1/20 0.75
RET P07949 10/20 0.69
KDR P35968 5/20 0.69
ALK Q9UM73 5/20 0.69
FLT3 P36888 4/20 0.69
PDPK1 O15530 2/20 0.69
PDGFRB P09619 4/20 0.68
CSF1R P07333 2/20 0.62
FGFR1 P11362 2/20 0.62
SRC P12931 2/20 0.62
FLT1 P17948 2/20 0.62
FGFR3 P22607 2/20 0.62
MAPK1 P28482 2/20 0.62
FLT4 P35916 2/20 0.62
PDGFRA P16234 2/20 0.62
ABL1 P00519 2/20 0.62
NTRK1 P04629 2/20 0.62
MEN1 O00255 1/20 0.62
NPC1 O15118 1/20 0.62
GMNN O75496 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16568378 0.86 TLK2 (0.82) TLK2RETKDRALKFLT3
SCHEMBL14519103 0.86 TLK2 (0.82) TLK2RETKDRALKFLT3
SCHEMBL5359704 0.83 HDAC3 (0.65) TLK2RETKDRALKFLT3
SCHEMBL5362637 0.83 TLK2 (0.77) TLK2RETKDRALKFLT3
SCHEMBL5478517 0.82 PDPK1 (1.00) TLK2RETKDRALKFLT3
SCHEMBL5203211 0.82 PDPK1 (1.00) TLK2RETKDRALKFLT3
SCHEMBL19979 0.82 RET (1.00) TLK2RETKDRALKFLT3
SCHEMBL19978 0.82 RET (1.00) TLK2RETKDRALKFLT3
SCHEMBL30685852 0.81 PDGFRB (0.68) TLK2RETKDRALKFLT3
SCHEMBL5369648 0.81 TLK2 (0.74) TLK2RETKDRALKFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed
EP-1247803-A2 Indolinone compounds suitable for modulation of protein kinases Sugen, Inc. (US) 2002-10-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK TLK2 48/4885RET 283/4885KDR 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.